-
Product Insights
Orr Dev – 616 & 640 Sixth Street Mixed-Use Tower – British Columbia
Equip yourself with the essential tools needed to make informed and profitable decisions with our Orr Dev - 616 & 640 Sixth Street Mixed-Use Tower - British Columbia report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...
-
Product Insights
OAM#37
The OAM#37 is a Coal mine in the United States. It is currently in operation. OAM#37 profile includes core details such as name, commodity, ore type, stage, type, owner and equity stakes, operator, size and location, as well as key operational data including production, capacity, strip ratio, start and end date, reserves and resources, grade. We also provide proprietary production forecasts, and counts of mobile equipment, plus selected key stakeholders and contact details.
-
Product Insights
OAM#40 Mine
The OAM#40 Mine is a Coal mine in the United States. It is currently in operation. OAM#40 Mine profile includes core details such as name, commodity, ore type, stage, type, owner and equity stakes, operator, size and location, as well as key operational data including production, capacity, strip ratio, start and end date, reserves and resources, grade. We also provide proprietary production forecasts, and counts of mobile equipment, plus selected key stakeholders and contact details.
-
Sector Analysis
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) – Global Drug Forecast and Market Analysis to 2025
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) – US Drug Forecast and Market Analysis to 2025
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) – 5EU Drug Forecast and Market Analysis to 2025
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) – Japan Drug Forecast and Market Analysis to 2025
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) – China Drug Forecast and Market Analysis to 2025
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.